Trexquant Investment LP Has $1.01 Million Holdings in Zai Lab Limited (NASDAQ:ZLAB)

Trexquant Investment LP cut its stake in shares of Zai Lab Limited (NASDAQ:ZLAB – Get Rating) by 29.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,433 shares of the company’s stock after selling 12,316 shares during the period. Trexquant Investment LP’s holdings in Zai Lab were worth $1,007,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. EverSource Wealth Advisors LLC acquired a new stake in Zai Lab during the third quarter worth approximately $28,000. Activest Wealth Management acquired a new stake in shares of Zai Lab in the third quarter valued at approximately $46,000. Vontobel Holding Ltd. acquired a new stake in shares of Zai Lab in the first quarter valued at approximately $210,000. Ensign Peak Advisors Inc raised its position in shares of Zai Lab by 7.3% in the third quarter. Ensign Peak Advisors Inc now owns 5,850 shares of the company’s stock valued at $200,000 after buying an additional 400 shares in the last quarter. Finally, ProShare Advisors LLC acquired a new stake in shares of Zai Lab in the third quarter valued at approximately $200,000. 59.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. dropped their price target on shares of Zai Lab from $96.00 to $79.00 and set an “overweight” rating for the company in a research report on Friday, November 18th.

Insider Activity at Zai Lab

In related news, Director William Lis sold 5,434 shares of Zai Lab stock in a transaction that occurred on Friday, March 3rd. The shares were sold at an average price of $38.31, for a total value of $208,176.54. Following the transaction, the director now directly owns 23,330 shares of the company’s stock, valued at $893,772.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Zai Lab news, insider Frazor Titus Edmondson III sold 7,965 shares of the business’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $40.55, for a total transaction of $322,980.75. Following the sale, the insider now owns 19,400 shares of the company’s stock, valued at $786,670. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William Lis sold 5,434 shares of the business’s stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $38.31, for a total transaction of $208,176.54. Following the sale, the director now directly owns 23,330 shares in the company, valued at approximately $893,772.30. The disclosure for this sale can be found here. Insiders have sold 24,879 shares of company stock valued at $990,357 over the last three months. 5.53% of the stock is owned by insiders.

Zai Lab Price Performance

Shares of NASDAQ:ZLAB opened at $31.70 on Tuesday. The company’s 50 day simple moving average is $40.15 and its 200 day simple moving average is $36.89. The stock has a market capitalization of $3.10 billion, a price-to-earnings ratio of -6.85 and a beta of 1.20. Zai Lab Limited has a 1 year low of $20.98 and a 1 year high of $53.95.

Zai Lab Company Profile

(Get Rating)

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. Its products include Zejula, Optune, Qinlock, and Nuzyra. The company was founded by Samantha Ying Du and Marietta Wu in April 2014 and is headquartered in Shanghai, China.